Faeth Therapeutics, Inc.
Small molecule inhibitors targeting multiple nodes of the PI3K/AKT/mTOR signaling pathway
- Sector
- Biotech
- Headquarters
- AUSTIN, TX
- Latest Form D
- $24.4M, Jan 2026
- Total capital
- $24.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $24.4M
- 1 Form D · last Jan 2026
- 9 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 24 pending · first 2024
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$24.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alex MorganDirectorNamed in SEC Form D filings
- Anand ParikhExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Jayson DallasDirectorNamed in SEC Form D filings
- Oliver MaddocksExecutive Officer, DirectorNamed in SEC Form D filings
- Robert GouldDirectorNamed in SEC Form D filings
- Stephen HahnDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 26- PendingMETHODS OF TREATING CANCER WITH PI3K/AKT/mTOR PATHWAY INHIBITORSUSPTOApplication 19565330
- PendingFormulations For Personalized Methods Of TreatmentUSPTOApplication 19003692
- PendingPersonalized Starvation Therapy For CancerUSPTOApplication 18676700
Show all 26 patent records
- METHODS OF TREATING CANCER WITH PI3K/AKT/mTOR PATHWAY INHIBITORSSep 17, 2026 · Application 19565330Pending
- Formulations For Personalized Methods Of TreatmentDec 4, 2025 · Application 19003692Pending
- Personalized Starvation Therapy For CancerMay 8, 2025 · Application 18676700Pending
- Combination Therapy For PIK3CA-ASSOCIATED Diseases Or DisordersMar 13, 2025 · Application 18638481Pending
- Formulations For Personalized Methods Of TreatmentFeb 11, 2025 · US 12,220,402Granted
- Personalized Modulation Therapy For CancerJan 16, 2025 · Application 18444504Pending
- Personalized Methods Of Treating CancerOct 8, 2024 · US 12,109,184Granted
- Personalized Modulation Therapy For CancerApplication PCTUS2022040588Pending
- Personalized Methods Of Treating CancerApplication 63295970Pending
- Dietary Regimens And Methods For Treatment Of Colorectal CancerApplication PCTUS2025022127Pending
- Personalized Starvation Therapy For CancerApplication 63280792Pending
- Combination Therapy For PIK3CA-ASSOCIATED Diseases Or DisordersApplication 63270297Pending
- Methods Of Determining Metabolic Targets And Designing Nutrient Modulating TreatmentsApplication 63246068Pending
- Personalized Modulation Therapy For CancerApplication 63234517Pending
- Personalized Starvation Therapy For CancerApplication 63234507Pending
- Personalized Methods Of Treating CancerApplication PCTUS2021035780Pending
- Formulations For Personalized Methods Of TreatmentApplication PCTUS2021035476Pending
- Personalized Methods Of Treating CancerApplication 63034679Pending
- Formulations For Personalized Methods Of TreatmentApplication 63034137Pending
- Personalized Starvation Therapy For CancerApplication 63288062Pending
- Hpd Inhibitor Compositions And Methods Of UseApplication PCTUS2025021891Pending
- Dietary Regimens And Methods For Treatment Of Colorectal CancerApplication 63571720Pending
- Personalized Methods Of Treating CancerApplication PCTUS2023060025Pending
- Personalized Starvation Therapy For CancerApplication PCTUS2022081307Pending
- Combination Therapy For PIK3CA-ASSOCIATED Diseases Or DisordersApplication PCTUS2022078418Pending
- Methods Of Determining Metabolic Targets And Designing Nutrient Modulating TreatmentsApplication PCTUS2022076643Pending
Related companies, and why
- MODULO BIO, INC.Similar federal contract value in Biotech · null in contracts
- KAYOTHERA INCSimilar federal contract value in Biotech · null in contracts
- XTRESSE, LLCSimilar federal contract value in Biotech · null in contracts
- Aethon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Consano Bio, Inc.Similar federal contract value in Biotech · null in contracts
- ORSOBIO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .